This profile is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Semaglutide is an FDA-approved prescription medication — it must be obtained through and used under the supervision of a licensed healthcare provider.
What Is Semaglutide?
Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk, approved by the FDA for the treatment of type 2 diabetes (as Ozempic, 2017) and chronic weight management in adults with obesity or overweight with a weight-related comorbidity (as Wegovy, 2021). An oral formulation is also available under the brand name Rybelsus for glycemic control in type 2 diabetes. It represents the first GLP-1 agonist engineered for once-weekly dosing, made possible by chemical modifications that dramatically extend the molecule's half-life from the native GLP-1 peptide's roughly two-minute half-life to approximately one week in humans.
The molecule was designed by attaching the native GLP-1 sequence to a fatty acid chain via a linker, which allows it to bind reversibly to albumin in the bloodstream — a strategy that dramatically slows renal clearance and protease degradation. Semaglutide shares roughly 94% sequence homology with endogenous human GLP-1 but has been modified at two positions to resist degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), which would otherwise cleave and inactivate the peptide within minutes. These structural innovations were a major engineering achievement in therapeutic peptide design and set the stage for an entirely new generation of metabolic drugs.
The clinical development program for semaglutide is among the most extensive in the history of metabolic medicine. The SUSTAIN trial series (for diabetes) and the STEP trial series (for obesity) together enrolled tens of thousands of patients across multiple countries and produced some of the most statistically robust weight-loss data ever reported for a pharmaceutical intervention. STEP 1, published in the New England Journal of Medicine in 2021, showed an average 14.9% reduction in body weight over 68 weeks with 2.4 mg/week semaglutide — a result that was considered transformative in a field where most prior pharmacological options had produced 5–8% weight loss at best.
Semaglutide's cultural impact has extended well beyond clinical medicine. Its commercial success as Ozempic and Wegovy has triggered global supply shortages, reshaped public discourse around obesity as a biological rather than behavioral condition, and catalyzed substantial investment in next-generation GLP-1 and dual/triple agonist development. Understanding semaglutide in depth is essential for anyone seriously researching the peptide landscape, as it established the proof-of-concept that pharmacological appetite and metabolic regulation could produce weight loss outcomes previously thought to require bariatric surgery.
How It Works
Semaglutide works by binding to and activating GLP-1 receptors, which are expressed in multiple tissues throughout the body including the pancreas, brain, gastrointestinal tract, heart, and kidneys. The most important sites of action for its weight loss effect are the hypothalamus and brainstem — specifically, GLP-1 receptors in the arcuate nucleus of the hypothalamus, the area postrema, and the nucleus of the solitary tract. Activation of these receptors produces a pronounced reduction in appetite by decreasing the firing of hunger-signaling neurons (NPY/AgRP) and increasing the activity of satiety-signaling neurons (POMC/CART). The practical result is that people on semaglutide experience substantially reduced hunger, faster satiation during meals, and fewer food cravings — effects that appear to be durable over the duration of treatment.
In the gastrointestinal tract, semaglutide activates GLP-1 receptors on smooth muscle and enteric neurons to slow gastric emptying — the rate at which food moves from the stomach into the small intestine. This mechanical slowing means meals take longer to digest, nutrient absorption is spread over a longer time window, and the subjective feeling of fullness after eating is prolonged. This gastric motility effect is also responsible for many of the most common side effects, including nausea and constipation, particularly during the dose titration phase when the body is adjusting to the compound.
In the pancreas, semaglutide stimulates insulin secretion from beta cells in a glucose-dependent manner — meaning it only triggers insulin release when blood glucose is elevated, which significantly reduces the risk of hypoglycemia compared to sulfonylureas and other insulin secretagogues. It also suppresses glucagon secretion from alpha cells, which reduces hepatic glucose output. These pancreatic effects are central to its efficacy in type 2 diabetes management. The cardiovascular benefits of semaglutide, demonstrated in the SUSTAIN-6 and SELECT trials, are thought to arise from a combination of direct GLP-1 receptor effects on the heart and vasculature, alongside the indirect benefits of reduced body weight, improved glycemic control, and reduced systemic inflammation.
Key Benefits Discussed in Research
Dosing Reference (Educational Only)
Semaglutide is an FDA-approved prescription medication. Dosing must be determined and supervised by a licensed physician. The information below reflects the approved prescribing information and published clinical trial protocols — it is not a recommendation for self-administration.
| Parameter | Common Research Range | Notes |
|---|---|---|
| Starting Dose | 0.25 mg/week | The 0.25 mg starting dose is not therapeutically active for weight loss — it is a tolerability initiation dose to minimize GI side effects during adjustment |
| Titration Schedule | Increase by 0.25 mg every 4 weeks | Standard Wegovy titration: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over approximately 16 weeks; slower titration is used if GI tolerability is an issue |
| Maintenance Dose (Obesity) | 2.4 mg/week (Wegovy) | FDA-approved maintenance dose for chronic weight management; the STEP trials used this dose for the 68-week primary efficacy endpoints |
| Maintenance Dose (Diabetes) | 0.5–1.0 mg/week (Ozempic) | Lower doses used for glycemic control; 2 mg/week Ozempic also approved in some markets for additional HbA1c reduction |
| Route | SubQ injection (weekly) or oral daily | Injectable pen (Ozempic/Wegovy) once weekly; Rybelsus oral tablets taken daily on an empty stomach with minimal water |
| Half-Life | Approximately 7 days | Engineered albumin-binding half-life enables once-weekly dosing; steady state is reached after approximately 4–5 weeks of weekly injections |
Want the Full Semaglutide Protocol?
Join SDBioHack and access community-validated protocols, sourcing checklists, and expert Q&A.
Side Effects & Safety Profile
Semaglutide's side effect profile is the best-characterized of any peptide in this library, given the scale of its clinical trial program and post-market pharmacovigilance data from millions of patients worldwide. The most common adverse effects are gastrointestinal in nature and are closely linked to the compound's mechanism of slowing gastric emptying. Nausea is the most frequently reported side effect, affecting a substantial minority of patients during the titration phase — typically peaking in the first 4–12 weeks and diminishing substantially as the body adapts. Vomiting, diarrhea, and constipation are also commonly reported. The slow titration schedule in the approved prescribing information is specifically designed to minimize GI intolerance by allowing the gastrointestinal system to adapt gradually to the compound's motility effects.
Two safety signals warrant particular attention. First, rodent studies with semaglutide and other GLP-1 agonists identified dose-dependent C-cell hyperplasia and medullary thyroid carcinoma in rat and mouse models. This finding has not been replicated in human clinical or epidemiological data, but the FDA has nonetheless required a black-box warning regarding thyroid C-cell tumors, and semaglutide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Second, pancreatitis has been reported in clinical trials at a low but nonzero rate — patients with a history of pancreatitis or significant alcohol use should exercise particular caution and discuss this history with their prescribing physician.
- Nausea — most common, typically peaks during titration, diminishes with time
- Vomiting, diarrhea, constipation — GI motility effects
- Decreased appetite and early satiety — expected pharmacodynamic effects
- Injection site reactions — mild and transient
- Fatigue, particularly early in treatment
- Rare: acute pancreatitis; gallbladder disease (cholelithiasis) at increased frequency vs. placebo
- Rare: hypoglycemia when combined with sulfonylureas or insulin
- Muscle loss concern: rapid weight loss can include lean mass loss; resistance training is recommended during treatment
Individuals with personal or family history of medullary thyroid carcinoma or MEN 2; those with prior or active pancreatitis; individuals with severe gastroparesis or other significant GI motility disorders; pregnant or breastfeeding individuals; those with hypersensitivity to semaglutide or any component of the formulation. Semaglutide requires a valid prescription and ongoing physician supervision — it is not appropriate for unsupervised self-administration.
Common Stacks & Pairings
As an FDA-approved prescription medication, semaglutide is typically discussed in the context of comprehensive lifestyle intervention programs rather than classic research peptide stacking. However, in the broader biohacking and metabolic optimization community, several complementary compounds are frequently discussed alongside it. These combinations are not studied in formal clinical trials and must be reviewed with a prescribing physician before consideration. The general philosophy is to support lean mass preservation, metabolic health, and GI tolerability during aggressive weight loss.
BPC-157 is sometimes discussed alongside semaglutide to support gastrointestinal healing and motility regulation, given the GI side effect burden of GLP-1 agonists. Tirzepatide and Retatrutide are more recent compounds that supersede semaglutide's efficacy profile in head-to-head comparisons and are relevant context for anyone researching this class. AOD-9604 targets a mechanistically distinct lipolytic pathway and may complement the appetite-regulation mechanism of semaglutide.
Frequently Asked Questions
Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021;384(11):989–1002. PMID: 33567185 (STEP 1 trial)
Marso SP, et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." New England Journal of Medicine. 2016;375(19):1834–1844. PMID: 27633186 (SUSTAIN-6 trial)
Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." New England Journal of Medicine. 2023;389(24):2221–2232. PMID: 37952131 (SELECT trial)
Rubino DM, et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial." JAMA. 2021;325(14):1414–1425. PMID: 33755728
Newsome PN, et al. "A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis." New England Journal of Medicine. 2021;384(12):1113–1124. PMID: 32966714 (NASH trial)